Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Daina Graybosch

How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery

BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.

Investors Business Daily

Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion

Moderna stock and BioNTech stock led a sell-off Monday among Covid vaccine makers after Pfizer slashed its full-year guidance.

Investors Business Daily

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death

The FDA placed a study of Arcellx's multiple myeloma drug on hold after a patient died, leading ACLX stock to crumble Tuesday.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment

BioNTech said Friday almost a third of patients with a hard-to-treat form of lung cancer responded to its treatment — and BNTX stock popped.

Investors Business Daily

Could Merck's Next Keytruda-Like Franchise Generate $10 Billion In Sales?

Two of Merck's new drugs could generate north of $10 billion in peak sales, an analyst said Tuesday.

Investors Business Daily

Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip

Novavax plans to update its Covid vaccine for new variants, and NVAX stock outperformed its vaccine stock rivals.

Investors Business Daily

Why 'Covid Fatigue' Isn't Enough To Keep BioNTech Down; Shares Surge On Upgrade

BioNTech snagged an upgrade Wednesday with an analyst saying "Covid fatigue" has obscured its non-pandemic efforts.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer

Newcomer Arcellx could rival Johnson & Johnson in multiple myeloma, an analyst said as the biotech popped to a two-month high.

Investors Business Daily

How Heart Drugs Could Pump $10 Billion Into Merck's Coffers

Merck stock has reinvigorated on the company's plans in heart disease. Will its efforts be enough as Keytruda goes off patent?

Investors Business Daily

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.